Table 2.
Immunological outcomes in the per-protocol population
| Seroconverted*, n/N (%, 95% CI) | Seroconversion difference†, percentage points (95% CI) | Geometric mean titre (95% CI) | Geometric mean titre ratio‡(95% CI) | ||
|---|---|---|---|---|---|
| Day 10 | .. | −10 (−21 to 0) | .. | 0·55 (0·35–0·86) | |
| Fractional dose | 87/118 (74%, 65–81) | .. | 51 (37–69) | .. | |
| Standard dose | 96/114 (84%, 76–90) | .. | 92 (67–127) | .. | |
| Day 28 | .. | −3 (−7 to 2) | .. | 0·86 (0·53–1·41) | |
| Fractional dose | 112/117 (96%, 90–99) | .. | 1391 (958–2019) | .. | |
| Standard dose | 115/117 (98%, 94–100) | .. | 1613 (1163–2236) | .. | |
| Day 365 | .. | −1 (−5 to 3) | .. | 0·71 (0·45–1·13) | |
| Fractional dose | 109/112 (97%, 92–100) | .. | 846 (599–1194) | .. | |
| Standard dose | 104/106 (98%, 93–100) | .. | 1191 (869–1634) | .. | |
*
Seroconversion is defined as ≥4-fold increase in neutralising antibody titre at each timepoint from baseline.
†
Seroconversion Difference=Fractional–Standard.
‡
Geometric mean titre ratio=Fractional ÷ Standard.